Message sent
Thank you for reaching out. I read everything personally and generally reply within about a week. If it's time-sensitive, mention that in your message and I'll do my best to move faster.
Contact
bpd.fyi is a patient-run resource. The research, clinical, and organizational work behind it is carried out by the Social Pain Institute — a nonprofit advancing the neuroscience of social pain and clinical access to the treatments that target it.
If you're here for personal reasons
This site is educational. It can't offer medical advice, treatment recommendations, or one-on-one support on individual cases. Most personal questions are already answered here:
- FAQ — the questions that come up most often
- Treatment and the clinician resources — what to read and bring to your own prescriber
- Research Registry — sign up to be contacted about future studies and surveys
If you're in crisis or struggling right now, please reach out to your care team or a local crisis line. This inbox isn't monitored for urgent or individual support.
Professional & partnership inquiries
Research, clinical, funding, training, and press inquiries are handled through the Social Pain Institute. If your work touches any of the areas below, I'd like to hear from you. Each note below explains what we're looking for — when you're ready, use the message form at the bottom of the page and it will reach the right place.
Researchers & clinical teams
This is the collaboration that matters most to the mission. If you study BPD, CPTSD, the endogenous opioid system, chronic suicidality, or self-harm — or you're weighing a pilot or trial of low-dose buprenorphine — SPI exists to lower your cost of starting. We can share a synthesized, citation-audited evidence base, a concept note for a stratified observational pilot, and a documented patient population that has already opted in to being recruited through our research registry.
Ketamine clinics & clinician educators
Recent trial evidence suggests low-dose buprenorphine may extend ketamine's antisuicidal effect. SPI is developing honest, non-promotional training to help clinics understand that emerging evidence — what it does and doesn't yet support, and the clinical and regulatory care responsible use requires. If you run or advise a clinic and want to help shape or pilot that training, get in touch.
Prescribers & clinicians
If you prescribe buprenorphine in other contexts and are considering its role in affective and interpersonal dysregulation, the prescriber guide is written for you. I can't offer clinical advice or answer questions about specific patients, but feedback on the guide, corrections, and case experience are all genuinely welcome.
Share feedback or case experience →
Funders & grantmakers
SPI is an early-stage nonprofit building the research, clinical, and community case for treating social pain at its mechanism. If your priorities include mental health, suicide prevention, or the opioid-system science behind them, I'm glad to share our theory of change and current plans. More about the organization is at socialpain.org.
Journalists & media
For background, interviews, or help understanding both the science and the patient perspective, reach out and mention your outlet and deadline.
Send a message
A short note about who you are and what you have in mind is plenty to start. The more specific the “type of inquiry,” the faster I can route and reply.
I read everything personally and generally reply within a week. Prefer to email directly? Show email address.